AXSM
Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$206.68
−0.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 776.6M | 638.5M | 385.7M | 270.6M | 50.0M |
| Cost of Revenue | 52.5M | 47.5M | 33.3M | 26.1M | 5.2M |
| Gross Profit | 724.0M | 591.0M | 352.4M | 244.5M | 44.8M |
| Operating Expenses | |||||
| R&D Expense | 187.9M | 183.3M | 187.1M | 97.9M | 57.9M |
| SG&A Expense | 712.7M | 570.6M | 411.4M | 323.1M | 159.3M |
| General & Admin Expense | 293.8M | — | 310.2M | 222.8M | — |
| Selling & Marketing Expense | 41.4M | — | 101.2M | 100.3M | — |
| Other Expenses | 12.1M | 6.4M | 34.5M | 55.3M | 7.4M |
| Total Operating Expenses | 912.6M | 760.3M | 633.0M | 476.4M | 224.6M |
| Cost and Expenses | 965.1M | 807.7M | 666.3M | 502.4M | 229.8M |
| Operating Income (EBIT) | (188.5M) | (169.2M) | (280.6M) | (231.8M) | (179.8M) |
| Non-Operating | |||||
| Interest Income | 2.0M | 9.4M | — | — | — |
| Interest Expense | 5.0M | 6.6M | 6.6M | 6.5M | 7.3M |
| Net Interest Income | (3.0M) | 2.8M | (6.6M) | (6.5M) | (7.3M) |
| Other Non-Op Income/Expense | (2.5M) | (14.5M) | (6.6M) | (6.5M) | (7.3M) |
| Non-Operating Income (excl Interest) | (2.5M) | 7.9M | — | — | — |
| EBT (Pre-Tax Income) | (191.1M) | (183.7M) | (287.1M) | (238.3M) | (187.1M) |
| Income Tax Expense | 558.0K | (530.0K) | 85.0K | 960.0K | — |
| Bottom Line | |||||
| Net Income | (191.6M) | (183.2M) | (287.2M) | (239.2M) | (187.1M) |
| Earnings from Cont. Ops | (191.6M) | (183.2M) | (287.2M) | (239.2M) | (187.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (191.6M) | (183.2M) | (287.2M) | (239.2M) | (187.1M) |
| Per Share | |||||
| Basic EPS | ($3.75) | ($3.68) | ($5.99) | ($5.27) | ($4.60) |
| Diluted EPS | ($3.75) | ($3.68) | ($5.99) | ($5.27) | ($4.60) |
| Revenue Per Share | $15.08 | $12.83 | $8.05 | $5.96 | $1.23 |
| Shares | |||||
| Basic Shares Outstanding | 51.5M | 49.7M | 47.9M | 45.4M | 40.7M |
| Diluted Shares Outstanding | 51.5M | 49.7M | 47.9M | 45.4M | 40.7M |
| Profitability Metrics | |||||
| EBITDA | (179.8M) | (168.1M) | (272.6M) | (225.0M) | (175.4M) |
| D&A | 6.3M | 9.1M | 8.0M | 6.8M | 4.4M |
| EBIT | (186.1M) | (177.1M) | (280.6M) | (231.8M) | (179.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026